SAFETY DATA SHEETS

This SDS packet was issued with item:

078910459

N/A

MATERIAL SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

Material Name: Ethosuximide Capsules

Trade Name: Zarontin
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as anticonvulsant

2. HAZARDS IDENTIFICATION

Appearance: Orange capsules
Signal Word: DANGER

Statement of Hazard:
May be harmful if swallowed.
May damage the unborn child.
Suspected of causing genetic defects.

Additional Hazard Information:
Short Term: May be harmful if swallowed. (based on animal data) .
Known Clinical Effects: Effects reported during clinical use included vomiting and diarrhea. Central nervous system effects such as dizziness, headache, insomnia, irritability and weakness have also been reported. Clinical use of this drug has caused decreased blood cell count, increased eosinophils in blood or tissue (eosinophilia), skin rash, Stevens Johnson Syndrome (epidermal necrosis and exfoliative dermatitis). May cause adverse effects on the developing fetus.

EU Indication of danger:
Harmful
Toxic to Reproduction: Category 2
Mutagenic: Category 3

EU Hazard Symbols:

EU Risk Phrases:
R22 - Harmful if swallowed.
R61 - May cause harm to the unborn child.
R68 - Possible risk of irreversible effects.

2. HAZARDS IDENTIFICATION

Australian Hazard Classification (NOHSC): Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Glycerin, USP	56-81-5	200-289-5	Not Listed	*
Ethosuximide	77-67-8	201-048-7	Xn, R22; Repr. Cat.2,R61; Mut. Cat.3,R68	250mg ***

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
FD & C Red No. 3 (E 127)	16423-68-0	240-474-8	Not Listed	*
Polyethylene glycol 400	25322-68-3	Not Listed	Not Listed	*
Gelatin	9000-70-8	232-554-6	Not Listed	*
Sorbitol	6706-59-8	Not Listed	Not Listed	*
D & C yellow No. 10	8004-92-0	Not Listed	Not Listed	*

Additional Information: * Proprietary
*** per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Glycerin, USP

ACGIH Threshold Limit Value (TWA)	10 mg/m^3
Australia TWA	10 mg/m^3
Belgium OEL - TWA	10 mg/m^3
Czech Republic OEL - TWA	10 mg/m^3
Estonia OEL - TWA	10 mg/m^3
Finland OEL - TWA	20 mg/m^3
France OEL - TWA	10 mg/m^3
Germany (DFG) - MAK	50 mg/m^3 inhalable fraction
Greece OEL - TWA	10 mg/m^3
Ireland OEL - TWAs	10 mg/m^3
OSHA - Final PELS - TWAs:	15 mg/m^3
Poland OEL - TWA	10 mg/m^3
Portugal OEL - TWA	10 mg/m^3
Spain OEL - TWA	10 mg/m^3

Ethosuximide

Pfizer OEL TWA-8 Hr:	2 mg/m^3

Polyethylene glycol 400

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Austria OEL - MAKs	1000 mg/m^3
Germany - TRGS 900 - TWAs	1000 mg/m^3
Germany (DFG) - MAK	1000 mg/m^3 inhalable fraction
Slovakia OEL - TWA	1000 mg/m^3
Slovenia OEL - TWA	1000 mg/m^3

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Capsule	**Color:**	Orange
Molecular Formula:	Mixture	**Molecular Weight:**	Mixture

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Glycerin, USP

Mouse Oral LD50 4090 mg/kg
Rat Oral LD50 12.6 g/kg
Rabbit Dermal LD50 > 10 g/kg
Rat Inhalation LC50 1hr > 570 mg/m^3
Rat Dermal LD 50 >21.9 g/kg

D & C yellow No. 10

11. TOXICOLOGICAL INFORMATION

Rat Oral LD50 2000 mg/kg

FD & C Red No. 3 (E 127)
Rat Oral LD50 1840 mg/kg
Mouse Oral LD50 1264 mg/kg

Ethosuximide
Mouse Oral LD50 1530 mg/kg
Rat Oral LD50 1950 mg/kg
Mouse Intravenous LD50 780 mg/kg
Mouse Intravenous LD50 1070 mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Glycerin, USP
Eye Irritation Rabbit Mild

Polyethylene glycol 400
Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Ethosuximide
3 Month(s) Dog Oral 100 mg/kg/day LOAEL Liver
26 Week(s) Rat Oral 676 mg/kg/day NOAEL None identified
26 Week(s) Dog Oral 100 mg/kg/day NOAEL None identified
26 Week(s) Monkey Oral 200 mg/kg/day NOAEL None identified
1 Year(s) Mouse Oral 136 mg/kg/day LOAEL Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Ethosuximide
Embryo / Fetal Development Rat 60 mg/kg/day LOEL Teratogenic
2 Generation Reproductive Toxicity Rat Oral 0.2 % LOAEL Not Teratogenic, Embryotoxicity
Embryo / Fetal Development Mouse Oral 60 mg/kg/day LOAEL Teratogenic
Prenatal & Postnatal Development Mouse Oral 50 mg/mL NOAEL Embryotoxicity, Reproductive toxicity, Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Ethosuximide
In Vitro Cytogenetics Human Negative
In Vivo Micronucleus Mouse Bone Marrow Positive

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Glycerin, USP
Oncorhynchus mykiss (Rainbow Trout) LD50 96 Hours 50 mg/L
Daphnia magna (Water Flea) EC50 24 Hours >500 mg/L
Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Symbol: T
EU Indication of danger: Harmful
Toxic to Reproduction: Category 2
Mutagenic: Category 3

EU Risk Phrases:

R22 - Harmful if swallowed.
R61 - May cause harm to the unborn child.
R68 - Possible risk of irreversible effects.

EU Safety Phrases:

S36/37 - Wear suitable protective clothing and gloves.
S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:
DANGER

15. REGULATORY INFORMATION

May be harmful if swallowed.
May damage the unborn child.
Suspected of causing genetic defects.

Canada - WHMIS: Classifications

WHMIS hazard class:
Class D, Division 2, Subdivision A

Glycerin, USP

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex V - Exemptions from the obligations of Register:	Present if not chemically modified, except they meet the criteria for classification as dangerous according to Directive 67/548/EEC, except those only classified as flammable [R10], as a skin irritant [R38] or as an eye irritant [R36], except they are persistent, bioaccumulative, and toxic or very persistent and very bioaccumulative in accordance with the criteria set out in Annex XIII, except they were identified in accordance with Article 59[1] at least two years previously as substances giving rise to an equivalent level of concern
EU EINECS/ELINCS List	200-289-5

FD & C Red No. 3 (E 127)

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	240-474-8

Ethosuximide

Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	201-048-7

Polyethylene glycol 400

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

Gelatin

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-554-6

D & C yellow No. 10

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.
R61 - May cause harm to the unborn child.
R68 - Possible risks of irreversible effects.

Data Sources: Pfizer proprietary drug development information. Safety data sheets for individual ingredients. Publicly available toxicity information.

Reasons for Revision: Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information. Updated Section 13 - Disposal Considerations. Updated Section 2 - Hazard Identification. Updated Section 4 - First Aid Measures. Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection.

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet

SAFETY DATA SHEET

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Ethosuximide Capsules

Trade Name: Zarontin
Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as anticonvulsant

Details of the Supplier of the Safety Data Sheet

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-800-879-3477

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161
Emergency telephone number:
International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Germ Cell Mutagenicity: Category 2
Reproductive Toxicity: Category 1B

EU Classification:

EU Indication of danger: Harmful
Toxic to Reproduction: Category 2
Mutagenic: Category 3

EU Risk Phrases:

R22 - Harmful if swallowed.
R61 - May cause harm to the unborn child.
R68 - Possible risk of irreversible effects.

Label Elements

Signal Word: Danger
Hazard Statements: H360D - May damage the unborn child
H341 - Suspected of causing genetic defects

Precautionary Statements: P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

Other Hazards No data available
Australian Hazard Classification (NOHSC): Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Glycerin, USP	56-81-5	200-289-5	Not Listed	Not Listed	*
Ethosuximide	77-67-8	201-048-7	Xn, R22; Repr. Cat.2,R61; Mut. Cat.3,R68	Acute Tox. 4, H302; Repr. 1B, H360D; Muta. 2, H341	250mg ***

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Polyethylene glycol 400	25322-68-3	Not Listed	Not Listed	Not Listed	*
Gelatin	9000-70-8	232-554-6	Not Listed	Not Listed	*
D & C yellow No. 10	8004-92-0	Not Listed	Not Listed	Not Listed	*
FD & C Red No. 3 (E 127)	16423-68-0	240-474-8	Not Listed	Not Listed	*
Sorbitol solution	50-70-4	200-061-5	Not Listed	Not Listed	*

Additional Information: * Proprietary
*** per tablet/capsule/lozenge/suppository
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Not applicable

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes, skin, and clothing. Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Glycerin, USP

Australia TWA	10 mg/m^3
Belgium OEL - TWA	10 mg/m^3
Czech Republic OEL - TWA	10 mg/m^3
Estonia OEL - TWA	10 mg/m^3
Finland OEL - TWA	20 mg/m^3
France OEL - TWA	10 mg/m^3
Germany (DFG) - MAK	50 mg/m^3
Greece OEL - TWA	10 mg/m^3
Ireland OEL - TWAs	10 mg/m^3
OSHA - Final PELS - TWAs:	15 mg/m^3
Poland OEL - TWA	10 mg/m^3
Portugal OEL - TWA	10 mg/m^3
Spain OEL - TWA	10 mg/m^3
Switzerland OEL -TWAs	50 mg/m^3

Ethosuximide

Pfizer OEL TWA-8 Hr:	2 mg/m^3

Polyethylene glycol 400

Austria OEL - MAKs	1000 mg/m^3
Germany - TRGS 900 - TWAs	1000 mg/m^3
Germany (DFG) - MAK	1000 mg/m^3 average molecular weight 200-600
Slovakia OEL - TWA	1000 mg/m^3
Slovenia OEL - TWA	1000 mg/m^3
Switzerland OEL -TWAs	1000 ppm

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Capsule	**Color:**	Orange
Odor:	No data available.	**Odor Threshold:**	No data available.
Molecular Formula:	Mixture	**Molecular Weight:**	Mixture

Solvent Solubility: No data available
Water Solubility: No data available
pH: No data available.
Melting/Freezing Point (°C): No data available
Boiling Point (°C): No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)
D & C yellow No. 10
No data available
FD & C Red No. 3 (E 127)
No data available
Ethosuximide
No data available
Polyethylene glycol 400
No data available
Glycerin, USP
No data available
Sorbitol solution
No data available
Gelatin
No data available
Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available
Vapor Pressure (kPa): No data available
Vapor Density (g/ml): No data available
Relative Density: No data available
Viscosity: No data available

Flammablity:
- **Autoignition Temperature (Solid) (°C):** No data available
- **Flammability (Solids):** No data available
- **Flash Point (Liquid) (°C):** No data available
- **Upper Explosive Limits (Liquid) (% by Vol.):** No data available
- **Lower Explosive Limits (Liquid) (% by Vol.):** No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available
Chemical Stability: Stable under normal conditions of use.
Possibility of Hazardous Reactions
- **Oxidizing Properties:** No data available
- **Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions.
- **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers
- **Hazardous Decomposition Products:** No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: May be harmful if swallowed. (based on animal data) .

Known Clinical Effects: Effects reported during clinical use included vomiting and diarrhea. Central nervous system effects such as dizziness, headache, insomnia, irritability and weakness have also been reported. Clinical use of this drug has caused decreased blood cell count, increased eosinophils in blood or tissue (eosinophilia), skin rash, Stevens Johnson Syndrome (epidermal necrosis and exfoliative dermatitis). May cause adverse effects on the developing fetus.

Acute Toxicity: (Species, Route, End Point, Dose)

D & C yellow No. 10
Rat Oral LD50 2000 mg/kg

FD & C Red No. 3 (E 127)
Rat Oral LD50 1840 mg/kg
Mouse Oral LD50 1264mg/kg

Ethosuximide
Mouse Oral LD50 1530 mg/kg
Rat Oral LD50 1950mg/kg
Mouse Intravenous LD50 780mg/kg
Mouse Intravenous LD50 1070mg/kg

Glycerin, USP
Mouse Oral LD50 4090 mg/kg
Rat Oral LD50 12.6 g/kg
Rabbit Dermal LD50 > 10 g/kg
Rat Inhalation LC50 1hr > 570 mg/m^3
Rat Dermal LD 50 > 21.9 g/kg

Sorbitol solution
Rat Oral LD50 15,900 mg/kg
Mouse Oral LD50 17,800mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Polyethylene glycol 400
Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Glycerin, USP
Eye Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Ethosuximide
3 Month(s) Dog Oral 100 mg/kg/day LOAEL Liver

11. TOXICOLOGICAL INFORMATION

26 Week(s) Rat Oral 676 mg/kg/day NOAEL None identified
26 Week(s) Dog Oral 100 mg/kg/day NOAEL None identified
26 Week(s) Monkey Oral 200 mg/kg/day NOAEL None identified
1 Year(s) Mouse Oral 136 mg/kg/day LOAEL Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Ethosuximide
Embryo / Fetal Development Rat 60 mg/kg/day LOEL Teratogenic
2 Generation Reproductive Toxicity Rat Oral 0.2 % LOAEL Not Teratogenic, Embryotoxicity
Embryo / Fetal Development Mouse Oral 60 mg/kg/day LOAEL Teratogenic
Prenatal & Postnatal Development Mouse Oral 50 mg/mL NOAEL Embryotoxicity, Reproductive toxicity, Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Ethosuximide
In Vitro Cytogenetics Human Negative
In Vivo Micronucleus Mouse Bone Marrow Positive

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Glycerin, USP
Oncorhynchus mykiss (Rainbow Trout) LD50 96 Hours 50 mg/L
Daphnia magna (Water Flea) EC50 24 Hours >500 mg/L

Aquatic Toxicity Comments: A greater than symbol (>) indicates that aquatic toxicity was not observed at the maximum dose tested.

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications
WHMIS hazard class:
Class D, Division 2, Subdivision A

Glycerin, USP

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex V - Exemptions from the obligations of Register:	Present if not chemically modified, except they meet the criteria for classification as dangerous according to Directive 67/548/EEC, except those only classified as flammable [R10], as a skin irritant [R38] or as an eye irritant [R36], except they are persistent, bioaccumulative, and toxic or very persistent and very bioaccumulative in accordance with the criteria set out in Annex XIII, except they were identified in accordance with Article 59[1] at least two years previously as substances giving rise to an equivalent level of concern
EU EINECS/ELINCS List	200-289-5

Ethosuximide

15. REGULATORY INFORMATION

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	201-048-7

Polyethylene glycol 400

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 3
EU EINECS/ELINCS List	Not Listed

Gelatin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	232-554-6

D & C yellow No. 10

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

FD & C Red No. 3 (E 127)

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	240-474-8

Sorbitol solution

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-061-5

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Germ cell mutagenicity-Cat.2; H341 - Suspected of causing genetic defects

Mutagenic: Category 3
Toxic to Reproduction: Category 2
Xn - Harmful

R22 - Harmful if swallowed.
R61 - May cause harm to the unborn child.
R68 - Possible risks of irreversible effects.

Data Sources:	Pfizer proprietary drug development information. Safety data sheets for individual ingredients. Publicly available toxicity information.
Reasons for Revision:	Updated Section 11 - Toxicology Information. Updated Section 2 - Hazard Identification. Updated Section 7 - Handling and Storage. Updated Section 3 - Composition / Information on Ingredients. Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 16 - Other Information.
Revision date:	13-Apr-2015
	Product Stewardship Hazard Communication
Prepared by:	Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet